Objective: To evaluate the effects of treatment of severe ocular injury with blood-stained cornea and no light perception by combined penetrating keratoplasty and vitreoretinal surgery, and to analyze the relevant factors. Methods: Records of 7 severely injured eyes of 7 patients with blood-stained cornea and no light perception who underwent penetrating keratoplasty combined with vitrectomy using a temporary keratoprosthesis were evaluated retrospectively. The preoperative visual acuity was no light perception in all injured eyes with a mean intraocular pressure of 3 mm Hg and a range from 2 to 5 mm Hg. The average interval from emergency wound closure to vitrectomy was 18 days with a range from 12 to 21 days. The mean follow-up was 28 months with a range from 26 to 30 months. Results: The postoperative visual acuity was better than light perception in 5 eyes with the best corrected visual acuity from light perception to 0.06. The retina was attached in 5 eyes. The postoperative intraocular pressure ranged from 5 to 15 mm Hg with a mean of 12 mm Hg; it was significantly higher than the preoperative one (p < 0.05). The postoperative complications mainly included temporary intraocular elevation (1 eye), corneal neovascularization (4 eyes), corneal rejection (4 eyes), retinal detachment (2 eyes) and ocular atrophy (2 eyes). Conclusion: Penetrating keratoplasty combined with vitrectomy using a temporary keratoprosthesis is a safe and effective method in treating severe ocular injury with blood-stained cornea and no light perception.

Keywords:
Vitrectomy, Penetrating keratoplasty, Eye injuries
1.
Yan H, Xu YH, Tian Q, et al: Vitrectomy for severe ocular injuries. Chin J Ocul Fundus Dis 2001;17:236.
2.
Dong FT, Dai RP: The surgical treatment of traumatized eyes with no light perception. Chin J Ophthalmol 2002;38:657–659.
3.
Wiedemann P, Konen W, Heimann K: Reconstruction of the anterior and posterior segment of the eye after massive injury. Ger J Ophthalmol 1994;3:84–89.
4.
Roters S, Szuman P, Hermes S, et al: Outcome of combined penetrating keratoplasty with vitreoretinal surgery for management of severe ocular injuries. Retina 2003;23:48–56.
5.
Lin XF, Wen XY, Wang ZF, et al: Vitreoretinal surgery for early traumatized eyes with no light perception. Chin J Ocul Fundus Dis 2000;16:251–252.
6.
Hui YN, Wang L, Shan WQ, et al: Exploratory vitrectomy for traumatized eyes with no light perception and dense vitreous hemorrhage. Chin J Ophthalmol 1996;32:450–452.
7.
Noorily SW, Foulks GN, McCuen BW: Results of penetrating keratoplasty associated with silicone oil retinal tamponade. Ophthalmology 1991;98:1186–1189.
8.
Karel I, Kalvodova B, Kuthan P: Results of penetrating keratoplasty in bullous silicone oil keratopathy. Graefes Arch Clin Exp Ophthalmol 1998;236:255–258.
9.
Mieler WF, Mittra RA: The role and timing of pars plana vitrectomy in penetrating ocular trauma. Arch Ophthalmol 1997;115:1191–1192.
10.
Carcia-Valenzuela E, Blair NP, Shapiro MJ, et al: Outcome of vitreoretinal surgery and penetrating keratopolasty using temporary keratoprosthesis. Retina 1999;19:424–429.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.